

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Roy R. Lobb

Application No.: 10/521,513

Filed: November 18, 2005

For: THERAPIES FOR
GLOMERULONEPHRITIS USING
INTERFERON-BETA-1 (*As
amended*)

Confirmation No.: 2848

Art Unit: 1647

Examiner: SEHARASEYON,
JEGATHEESAN

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby brings to the Examiner's attention the references listed on the accompanying substitute form for PTO/SB/08. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making the appropriate notations on the attached form. Copies of references BD, BE, BF, EA, EB, and EC are submitted herewith.

References BD, BE, and BF are non-English documents. The identical references were previously cited to the Office in an Information Disclosure Statement, but were listed as not considered by the Examiner in an Office Action dated April 16, 2008. Pursuant to MPEP 609.01, Applicant submits herewith English language abstracts for references BD, BE, and BF as required concise explanations of relevance, as is presently understood by Applicant's representative, or

individual designated in 37 CFR § 1.56(c) most knowledgeable about the content of the references. The English language abstracts for references BD, BE, and BF are listed as references EA, EB, and EC, respectively, on the accompanying substitute form for PTO/SB/08.

References EA, EB, and EC are also being submitted in compliance with 37 CFR § 1.98(a)(3)(ii), as copies of written English-language translations of references BD, BE, and BF, or portions thereof, within the possession, custody, or control of, or readily available to any individual designated in § 1.56(c).

Applicant has listed the dates of publication on the attached substitute form for PTO/SB/08 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the dates indicated.

This submission does not represent that a search has been made or that no other art exists. Nor does it constitute an admission that any of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of the document.

Because this Information Disclosure Statement is being filed after the mailing of a first Office action on the merits but before the mailing date of any of a final action, the fee set forth in § 1.17(p) is submitted herewith. If any further fees are due, the Director is hereby authorized to charge the deficiency to our **Deposit Account, No. 06-1448, Reference BII-001.01.**

Dated: September 25, 2008

Respectfully submitted,

By /Janann Y. Ali/

Janann Y. Ali, Ph.D.

Registration No.: 54,958

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1749

Agent for Applicant